SR-419 is under clinical development by Shanghai SIMR Biotech and currently in Phase II for Peripheral Neuropathic Pain. According to GlobalData, Phase II drugs for Peripheral Neuropathic Pain have a 19% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SR-419’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SR-419 is under development for the treatment of peripheral neuropathic pain of postherpetic neuralgia (PHN). It is administered orally.
Shanghai SIMR Biotech overview
Shanghai SIMR Biotech is an innovation-oriented biotech dedicated to the discovery and development of new drugs for pain and other nervous system related diseases. The company is headquartered in Shanghai, China.
For a complete picture of SR-419’s drug-specific PTSR and LoA scores, buy the report here.